Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects

British Journal of Clinical Pharmacology

Volumn 56, Issue 2, 2003, Pages 184-187

  Sathirakul, Korbtham ^a,c   Chan, Clark ^a   Teng, Leyan ^a   Bergstrom, Richard F ^b   Yeo, Kwee Poo ^a   Wise, Stephen D ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

CYP1A2; Olanzapine; Pharmacokinetics; Race

Indexed keywords

CYTOCHROME P450 1A2; LY 170222; OLANZAPINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CAUCASIAN; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIAZEPINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; PIRENZEPINE;

EID: 0042530223     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01857.x     Document Type: Article

References (11)

1. Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. Br J Psychiatry Suppl 1999; 37: 30-35.
2. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-193.
3. Weigmann H, Gerek S, Zeisig A, Muller M, Hartter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001; 23: 410-413.
4. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observation on possible mechanism. Eur J Clin Pharamcol 1998; 54: 639-643.
5. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. IARC Sci Publ 1999; 148: 173-195.
6. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997; 86: 1328-1333.
7. Catlow JT, Barton RD, Clemens M et al. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995; 668: 85-90.
8. Bartoli A, Xiaodong S, Gatti G et al. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 1996; 18: 586-591.
9. Kalow W, Tang BK. Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
10. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferase and human liver microsomes. Hum Psychopharmacol 2002; 17: 233-238.
11. Ghoneim MM, Korttila K, Chiang CK et al. Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 1981; 29: 749-756.